Syndax Reports Third-Quarter 2026 Financial Results and Business Update
Syndax reported total revenue of $83.3 million in 3Q26, up 82% year over year.
Story updates
09:09:00 PM UTC
SquawkNews
Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase —— Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT2Ar acute leukemia; 20% q/q growth in new patients —— Niktimvo™ (axatilimab-csfr) net revenue of $67…